News & Updates
Filter by Specialty:

Long-term risankizumab safe, effective in moderate-to-severe plaque psoriasis
20 Dec 2023
byStephen Padilla
Treatment with risankizumab in the long term shows lasting efficacy against moderate-to-severe plaque psoriasis and has good tolerability, according to the LIMMitless study.
Long-term risankizumab safe, effective in moderate-to-severe plaque psoriasis
20 Dec 2023
Modified PDT on par with isotretinoin therapy for moderate-to-severe acne vulgaris
22 Nov 2023
The modified red light 5-aminolevulinic acid photodynamic therapy (M-PDT) delivers a faster onset of improvement, similar overall efficacy, good tolerability, and comparable durability of response when compared with low-dose isotretinoin (ISO) therapy in patients with moderate-to-severe acne vulgaris, reports a study.